Q&A with Richard Shor, President of SaniSure - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Richard Shor, President of SaniSure
Q&A with Richard Shor, President of SaniSure.

Pharmaceutical Technology
Volume 36, Issue 12


Richard Shor

PharmTech:

How has the increasing focus on biopharmaceuticals affected your business?

Shor:

In the sense that biopharmaceuticals are now a growth industry as opposed to the traditional chemical–pharmaceutical industry, it has impacted us greatly. Single-use process components are ideal for the biopharmaceutical arena. Batches are typically smaller and most of the processes are not using chemicals that will affect the components we provide.

PharmTech:

How will the industry remain innovative as it reduces spending on research?

Shor:

We have not seen any decline in innovations; however, it is now coming from other sources. What we are seeing is the partnership and licensing of a molecule to a start-up or small biotechnology company. This model allows the big companies to reduce their R&D budgets and risk exposure while allowing the smaller companies to get funding through private equity or other sources. If the product is a success, the investors win as well as the large biotechnology companies that will purchase the smaller company in the end.

PharmTech:

Do you see a new industry trend emerging?

Shor:

Regulatory compliance has become a big part of our customers' requirements. Biotechnology companies are demanding much tighter control and assurance of our products. As a supplier of single-use components and systems, SaniSure is now being asked to have control of our supplier base and the raw materials they are using. The onus is on us to assure a consistent and stable level of quality and control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here